Renaissance Technologies
ALLO icon

Renaissance Technologies’s Allogene Therapeutics ALLO Stock Holding History

Renaissance Technologies’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.98M Buy
3,834,312
+1,694,984
+79% +$3.72M 0.01% 1182
2026
Q1 		$5.22M Sell
2,139,328
-47,756
-2% -$95.7K 0.01% 1359
2025
Q4 		$3M Sell
2,187,084
-706,728
-24% -$932K ﹤0.01% 1629
2025
Q3 		$3.59M Buy
2,893,812
+1,223,800
+73% +$1.46M ﹤0.01% 1678
2025
Q2 		$1.89M Buy
1,670,012
+113,312
+7% +$151K ﹤0.01% 2146
2025
Q1 		$2.27M Buy
1,556,700
+1,002,159
+181% +$1.89M ﹤0.01% 1921
2024
Q4 		$1.18M Sell
554,541
-87,468
-14% -$216K ﹤0.01% 2398
2024
Q3 		$1.8M Sell
642,009
-1,105,946
-63% -$2.95M ﹤0.01% 2095
2024
Q2 		$4.07M Buy
1,747,955
+1,351,055
+340% +$3.99M 0.01% 1442
2024
Q1 		$1.77M Sell
396,900
-61,748
-13% -$258K ﹤0.01% 2111
2023
Q4 		$1.47M Buy
458,648
+428,366
+1,415% +$1.21M ﹤0.01% 2153
2023
Q3 		$96K Sell
30,282
-221,618
-88% -$971K ﹤0.01% 3255
2023
Q2 		$1.25M Sell
251,900
-176,800
-41% -$956K ﹤0.01% 2329
2023
Q1 		$2.12M Sell
428,700
-11,400
-3% -$73.1K ﹤0.01% 1990
2022
Q4 		$2.77M Buy
+440,100
New +$4.07M ﹤0.01% 1876
2022
Q2 		– Sell
-974,700
Closed -$8.88M – 4188
2022
Q1 		$8.88M Buy
+974,700
New +$10.2M 0.01% 1195
2021
Q3 		– Sell
-704,400
Closed -$18.4M – 3440
2021
Q2 		$18.4M Buy
+704,400
New +$20.1M 0.02% 801
2020
Q4 		– Sell
-83,900
Closed -$3.16M – 3356
2020
Q3 		$3.16M Buy
83,900
+58,700
+233% +$2.21M ﹤0.01% 1853
2020
Q2 		$1.08M Buy
+25,200
New +$911K ﹤0.01% 2499

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies's ALLO Position: Q2 2026 in Review

Renaissance Technologies increased its Allogene Therapeutics (ALLO) stake by 79% in Q2 2026, buying an estimated $3.72M and bringing the position to 3,834,312 shares worth $7.98M. The position accounts for 0.01% of the portfolio, ranked #1182.

Renaissance Technologies first reported a position in ALLO in Q2 2020 and has held it in 19 quarters since. The position peaked at $18.4M in Q2 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Renaissance Technologies held 3,834,312 shares of Allogene Therapeutics worth $7.98M as of Q2 2026.
  • Renaissance Technologies bought 1,694,984 Allogene Therapeutics shares in Q2 2026, an estimated $3.72M.
  • Allogene Therapeutics made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1182 holding.
  • Renaissance Technologies first reported a position in Allogene Therapeutics in Q2 2020 and has held it in 19 quarters since.
  • Renaissance Technologies's Allogene Therapeutics position peaked at $18.4M in Q2 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.